NPM1 and acute myeloid leukemia: Taking into account the proven influence of concomitant mutations on the outcome, the presence of the WT1 and NPM1 mutations was included in the stratification of the risk groups in the consecutive protocols (AML-BFM 2012 and AML-BFM 2019—second period).